osteoporosis

(redirected from Postmenopausal osteoporosis)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Words related to osteoporosis

abnormal loss of bony tissue resulting in fragile porous bones attributable to a lack of calcium

References in periodicals archive ?
Logistic regression analysis showed that the age and NLR level were risk factors for postmenopausal osteoporosis.
Technavio's report, Global Postmenopausal Osteoporosis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts.
Accordingly, the inhibition of osteoclast differentiation and activation would be a therapeutic strategy for postmenopausal osteoporosis.
Risedronate is approved for the prevention and treatment of postmenopausal osteoporosis, treatment for osteoporosis in men, and prevention and treatment of glucocorticoid-induced osteoporosis.
This comprehensive literature review demonstrates the possible association between postmenopausal osteoporosis and periodontal disease: postmenopausal women with low systemic BMD tended to have greater loss of alveolar bone and clinical attachment.
Postmenopausal osteoporosis is characterized by low levels of estrogen and high levels of bone mineralization markers.
14) It is approved for the treatment of postmenopausal osteoporosis, osteoporosis in men, and for patients with GIO.
Montserrat Otero, a PhD holder in Physical Activity and Sports Sciences of the UPV/EHU-University of the Basque Country studied 68 women with postmenopausal osteoporosis of the age group 50 - 72, of whom 34 were randomly assigned to the Exercise Group and 34 to the Control Group.
Finally, it is important to recognize the compelling evidence showing that treating postmenopausal osteoporosis can significantly reduce fracture risk.
Key words: Postmenopausal osteoporosis, quality of life, QUALEFFO, bone mineral density
All of the drugs approved by the US Food and Drug Administration (FDA) for the prevention and treatment of postmenopausal osteoporosis have demonstrated clinical benefit in randomized, placebo-controlled clinical trials.
Vitamin K2, raloxifene, and bisphosphonates, such as etidronate, alendronate, and risedronate, are widely used in the treatment of postmenopausal osteoporosis in Japan.
This new medicine will provide an important therapeutic option in the treatment of postmenopausal osteoporosis in women at increased risk of fractures.
In particular, we believe that Prolia will offer patients with postmenopausal osteoporosis at increased risk for fracture an important alternative to current treatments.
Full browser ?